Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL)

被引：1
|
作者：
Duvic, M.
Vanaclocha, F.
Bernengo, M. G.
Okada, C.
Breneman, D.
Zinzani, P. L.
Zhang, L.
Bopp, K.
Laird, G.
Hirawat, S.
Prince, M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Turin, Turin, Italy
[3] Portland VA Med Ctr, Portland, OR USA
[4] Univ Cincinnati, Cincinnati, OH USA
[5] Ist Ematol Oncol Med, Bologna, Italy
[6] Novartis Pharmaceut, Florham Pk, NJ USA
[7] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8555
引用
收藏
页数：1
相关论文
共 50 条
  • [21] An open-label phase II study of intravenous bortezomib and oral panobinostat (LBH589) in adult patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) or NK/T-cell lymphoma (NKL) after failure of conventional chemotherapy.
    Tan, D. C.
    Chan, P.
    Ng, B. L.
    Yap, B. K.
    Chan, Y. H.
    Koh, L. P.
    Wahid, F. A.
    Lim, S. T.
    Chin, N. S.
    Kim, W. S.
    Tan, S. Y.
    Goh, Y. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients
    Flinn, Ian W.
    Lang, Evan
    Raefsky, Eric
    Boccia, Ralph
    Macias-Perez, Ines M.
    Burris, Howard A., III
    Hainsworth, John D.
    BLOOD, 2010, 116 (21) : 1636 - 1637
  • [23] A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
    Fukutomi, Akira
    Hatake, Kiyohiko
    Matsui, Kaoru
    Sakajiri, Sakura
    Hirashima, Tomonori
    Tanii, Hiromi
    Kobayashi, Ken
    Yamamoto, Nobuyuki
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1096 - 1106
  • [24] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Reinhert, A.
    Daud, A.
    Munster, P. N.
    EJC SUPPLEMENTS, 2010, 8 (07): : 130 - 131
  • [25] A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
    Akira Fukutomi
    Kiyohiko Hatake
    Kaoru Matsui
    Sakura Sakajiri
    Tomonori Hirashima
    Hiromi Tanii
    Ken Kobayashi
    Nobuyuki Yamamoto
    Investigational New Drugs, 2012, 30 : 1096 - 1106
  • [26] A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumours
    Okamoto, N.
    Hatake, K.
    Yamamoto, N.
    Takahashi, S.
    Boku, N.
    Kobayashi, K.
    Sakatani, K.
    Hirashima, T.
    Matsui, K.
    EJC SUPPLEMENTS, 2008, 6 (12): : 133 - 133
  • [27] LBH589, a novel histone deacetylase inhibitor (HDACi), treatment of patients with cutaneous T-cell lymphoma (CTCL). Changes in skin gene expression profiles related to clinical response following therapy.
    Prince, H. M.
    George, D. J.
    Johnstone, R.
    Williams-Truax, R.
    Atadja, P.
    Zhao, C.
    Dugan, M.
    Culver, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 422S - 422S
  • [28] Phase II trial of panobinostat (LBH589) in patients (pts) with refractory metastatic colorectal cancer (MCRC).
    Gold, Philip Jordan
    Smith, David A.
    Iriarte, Desiree
    Boatman, Barry
    Kaplan, Henry G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [29] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, A. P.
    Thomas, S.
    Ryan, C. J.
    Jahan, T. M.
    DuBois, S. G.
    Chan, J. K.
    Thurn, K. T.
    Collisson, E. A.
    Reinert, A.
    Daud, A.
    Munster, P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer
    Feld, R.
    Woo, M. M.
    Shepherd, F. A.
    Leighl, N. B.
    Elshtein, R.
    Hengelage, T.
    Hirawat, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345